Literature DB >> 27580884

"Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation.

Ben Freedman1, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27580884     DOI： 10.1160/TH16-08-0658

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  13 in total

1.  The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.

Authors:  Laura Fanning; Jenni Ilomäki; J Simon Bell; Pēteris Dārziņš
Journal:  Eur J Clin Pharmacol       Date:  2017-07-27       Impact factor: 2.953

2.  Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.

Authors:  Ahsan A Khan; Gregory Y H Lip
Journal:  Ann Transl Med       Date:  2017-12

3.  Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.

Authors:  José Miguel Rivera-Caravaca; Vanessa Roldán; Marta Romera; María Asunción Esteve-Pastor; Mariano Valdés; Gregory Y H Lip; Vicente Vicente; Francisco Marín
Journal:  J Gen Intern Med       Date:  2018-03-22       Impact factor: 5.128

Review 4.  Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention.

Authors:  Farhan Shahid; Eduard Shantsila; Gregory Y H Lip
Journal:  F1000Res       Date:  2016-12-20

Review 5.  Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.

Authors:  Tatjana S Potpara; Nikolaos Dagres; Nebojša Mujović; Dragan Vasić; Milika Ašanin; Milan Nedeljkovic; Francisco Marin; Laurent Fauchier; Carina Blomstrom-Lundqvist; Gregory Y H Lip
Journal:  Adv Ther       Date:  2016-12-08       Impact factor: 3.845

6.  Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.

Authors:  Xiaoyan Shawn Li; Steve Deitelzweig; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2017-03-16       Impact factor: 5.249

7.  Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.

Authors:  Alpesh Amin; Alessandra B Garcia Reeves; Xiaoyan Li; Amol Dhamane; Xuemei Luo; Manuela Di Fusco; Anagha Nadkarni; Keith Friend; Lisa Rosenblatt; Jack Mardekian; Xianying Pan; Huseyin Yuce; Allison Keshishian
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

8.  Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.

Authors:  So-Ryoung Lee; Eue-Keun Choi; Kyung-Do Han; Jin-Hyung Jung; Seil Oh; Gregory Y H Lip
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

9.  Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.

Authors:  Xiaoyan Li; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y H Lip; Steve Deitelzweig
Journal:  PLoS One       Date:  2018-01-26       Impact factor: 3.240

10.  Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores.

Authors:  José Miguel Rivera-Caravaca; Vanessa Roldán; María Asunción Esteve-Pastor; Mariano Valdés; Vicente Vicente; Gregory Y H Lip; Francisco Marín
Journal:  J Am Heart Assoc       Date:  2017-07-20       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.